What is a GLP-1, and what are the types of GLP-1 medications?
A GLP-1 medication is a drug that copies GLP-1, a hormone your gut releases when you eat. The full name is GLP-1 receptor agonist (GLP-1 RA): it switches on the same receptor the natural hormone does. These medications are used for type 2 diabetes and obesity, and outcome trials show they lower cardiovascular and kidney risk. They come in three main types: short-acting, long-acting, and the newer dual and triple agonists. In two decades of practicing medicine, few drug classes have changed my practice as much as this one.
By Dr. Ty Tallman, NMD · Integrative Medical Partners, Mesa, AZ · Updated November 17, 2026
The GLP-1 medications at a glance
| Medication | Type | How often |
|---|---|---|
| Exenatide | GLP-1, short-acting (also an extended-release form) | Twice daily, or weekly for extended-release |
| Lixisenatide | GLP-1, short-acting | Once daily |
| Liraglutide | GLP-1, long-acting | Once daily |
| Dulaglutide | GLP-1, long-acting | Once weekly |
| Semaglutide | GLP-1, long-acting | Once weekly by injection; also a daily tablet |
| Tirzepatide | Dual agonist: GLP-1 and GIP | Once weekly |
| Retatrutide | Triple agonist: GLP-1, GIP and glucagon (investigational) | Still in trials |
Breaking down the name
- GLP-1 (glucagon-like peptide-1): a short protein hormone released by cells in your lower intestine when you eat. It is an incretin, meaning a gut hormone that boosts insulin release after a meal.
- Receptor: the docking site for GLP-1. It is found in the pancreas, gut, brain, heart, kidneys, blood vessels and lungs, which is why these medications do far more than lower blood sugar.
- Agonist: a drug that switches a receptor on, the same way the natural hormone does.
Why you need a medication instead of the natural hormone
Your own GLP-1 lasts only about two to three minutes in the blood before an enzyme called DPP-4 breaks it down. GLP-1 medications are chemically modified so the enzyme cannot break them down as fast and the kidneys clear them more slowly. Semaglutide, for example, carries a fatty-acid chain that lets it ride on a blood protein. Those changes are what make once-a-day or once-a-week dosing possible.
What they do in your body
- Pancreas: more insulin and less glucagon, but only when blood sugar is high. That is why low blood sugar is uncommon when they are used alone.
- Liver: makes less glucose.
- Stomach: food leaves more slowly. This causes much of the nausea, and it matters before any procedure with sedation.
- Brain: stronger fullness signals and less appetite, which is the main reason for weight loss.
- Heart, blood vessels and kidneys: lower blood pressure, less inflammation and healthier vessel lining, which likely add to heart and kidney protection.
The three types, in plain terms
- Short-acting GLP-1s (exenatide, lixisenatide): the first generation, taken once or twice a day.
- Long-acting GLP-1s (liraglutide, dulaglutide, semaglutide): steadier levels, taken daily or weekly. Most of the heart and kidney outcome evidence sits here.
- Dual and triple agonists (tirzepatide, retatrutide): these act on GLP-1 plus a second or third hormone receptor. Tirzepatide adds GIP, the other incretin hormone, and produces more weight loss than GLP-1-only medications. Retatrutide adds glucagon as well and is still investigational.
Go deeper: semaglutide vs. tirzepatide, what retatrutide is, GLP-1 benefits beyond weight loss, and which weight loss medications are safe.
GLP-1s are not the same as the “gliptins”
DPP-4 inhibitors, the “gliptins” such as sitagliptin, work by slowing the breakdown of your own GLP-1. That raises your natural levels only modestly. GLP-1 medications reach levels far above what your body makes, which explains their much larger effect on weight and on cardiovascular outcomes.
Side effects to know
Nausea, vomiting and diarrhea are the most common. Loss of muscle and bone is the one I watch most closely, especially past 50. Our full page on GLP-1 side effects and how we manage them covers the rest.
How we choose in this office
We match the medication to the person, not the headline. Your labs, your health history, your goals and how you respond in the first month decide which type fits, and we check in every 30 days to adjust. Every patient is screened before starting. We do not publish doses.
GLP-1 medications
The right GLP-1 for you, chosen by your physician with a check-in every 30 days.
GLP-1 plans $349/month · first month $449
Questions first? Text us. Ready? Book now. · 1910 S Stapley Dr #120, Mesa, AZ 85204
Frequently asked questions
What does GLP-1 RA stand for?
Glucagon-like peptide-1 receptor agonist: a medication that switches on the receptor for GLP-1, a natural gut hormone.
Is tirzepatide a GLP-1?
Partly. Tirzepatide is a dual agonist: it acts on the GLP-1 receptor and on the GIP receptor, the second incretin hormone.
Is Januvia (sitagliptin) a GLP-1?
No. It is a DPP-4 inhibitor. It protects your own GLP-1 from being broken down, which gives a much smaller effect than a GLP-1 medication.
Are all GLP-1 medications injections?
Most are. Semaglutide also comes as a daily tablet.
Which GLP-1 is best?
It depends on your goal and your health picture. The strongest evidence differs by condition, which we lay out on our GLP-1 longevity and microdosing page. The right choice is made with your labs in hand.
To Health and Wellness,
Dr. Ty Tallman
This page is educational and is not a substitute for individualized medical advice, diagnosis, or treatment. · Leer en español
References
The New England Journal of Medicine, 2026 — review of GLP-1 receptor agonists.
Drugs, 2026 — safety and tolerability of GLP-1 receptor agonists.
Nature Reviews Endocrinology, 2024 — targeting the incretin system in obesity and type 2 diabetes.
The Journal of Clinical Endocrinology and Metabolism, 2025 — cardiometabolic medications in cardiovascular-kidney-metabolic syndrome.
Current Gastroenterology Reports, 2025 — gastrointestinal motility effects of GLP-1 receptor agonists.
Diabetes, Obesity & Metabolism, 2016 — GLP-1 receptor agonists versus DPP-4 inhibitors, modes of action.